SCHEMBL15664996

SCHEMBL15664996

COc1cc(OC)cc(-c2ncn(-c3cc(OC)c(OC)c(OC)c3)c2-c2ccc(OC)c(F)c2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 4/20 0.47
PTGS1 P23219 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.41
KATNA1 O75449 1/20 0.40
USP2 O75604 1/20 0.39
PDGFRB P09619 1/20 0.39
PDGFRA P16234 1/20 0.39
TUBB4A P04350 1/20 0.38
TUBB P07437 1/20 0.38
TUBA3C P0DPH7 1/20 0.38
TUBA1B P68363 1/20 0.38
TUBA4A P68366 1/20 0.38
TUBB4B P68371 1/20 0.38
TUBB3 Q13509 1/20 0.38
TUBB2A Q13885 1/20 0.38
TUBB8 Q3ZCM7 1/20 0.38
TUBA3E Q6PEY2 1/20 0.38
TUBA1A Q71U36 1/20 0.38
TUBA1C Q9BQE3 1/20 0.38
TUBB6 Q9BUF5 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15664840 0.87 TUBB4A (0.48) KATNA1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL27902990 0.86 TUBB4A (0.41) KATNA1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL28089068 0.83 PTGS2 (0.43) PTGS2PTGS1L3MBTL1USP2PDGFRB
SCHEMBL15664486 0.82 TUBB4A (0.47) KATNA1PDGFRBPDGFRATUBB4ATUBB
SCHEMBL27934206 0.81 PHF8 (0.50) PTGS2PTGS1L3MBTL1USP2PDGFRB
SCHEMBL15664914 0.79 TUBB4A (0.55) KATNA1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL15665005 0.79 KATNA1 (0.42) L3MBTL1KATNA1TUBB4ATUBBTUBA3C
SCHEMBL7113747 0.79 PHF8 (0.53) PTGS2PTGS1L3MBTL1PDGFRBPDGFRA
SCHEMBL15664969 0.79 PDGFRB (0.39) PTGS2PTGS1L3MBTL1USP2PDGFRB
SCHEMBL15664796 0.78 TUBB4A (0.48) L3MBTL1KATNA1TUBB4ATUBBTUBA3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9139574-B2 Tumor targeted drug combretastatin A4 derivative NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) 2015-09-22 US claimed
US-20140128384-A1 TUMOR TARGETED DRUG COMBRETASTATIN A4 DERIVATIVE NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) 2014-05-08 US claimed
EP-2730565-B1 TUMOR TARGETED DRUG COMBRETASTATIN A4 DERIVATIVE NANJING SANHOME PHARMACEUTICAL CO LTD (CN) 2017-04-26 EP disclosed
US-9139574-B2 Tumor targeted drug combretastatin A4 derivative NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) 2015-09-22 US disclosed
EP-2730565-A1 TUMOR TARGETED DRUG COMBRETASTATIN A4 DERIVATIVE Nanjing Sanhome Pharmaceutical Co., Ltd. (CN) 2014-05-14 EP disclosed
US-20140128384-A1 TUMOR TARGETED DRUG COMBRETASTATIN A4 DERIVATIVE NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) 2014-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140128384-A1 TUMOR TARGETED DRUG COMBRETASTATIN A4 DERIVATIVE TUBA4A, TUBGCP4, TUBB4A PTGS2 4150/4885PTGS1 3527/4885L3MBTL1 3683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.